Expanding therapeutic options: lenacapavir + bictegravir as a potential treatment for HIV
Expert Opin Pharmacother. 2024 Jan 2:1-8. doi: 10.1080/14656566.2023.2294918. Online ahead of print.ABSTRACTINTRODUCTION: Treatment for people with HIV/AIDS has radically evolved since the introduction of the first antiretrovirals. One newly approved antiretroviral is lenacapavir, which targets the viral capsid. Lenacapavir is currently approved as a therapeutic addition for subjects who are treatment-experienced, and who have developed resistance to multiple antiretrovirals. It is available both as a daily oral tablet and a once every 6-month subcutaneous injection. It is currently undergoing clinical trials in combinatio...
Source: Expert Opinion on Pharmacotherapy - January 2, 2024 Category: Drugs & Pharmacology Authors: Jessica Doan Shannon Brunzo-Hager Brittany Satterly Theodore James Cory Source Type: research
Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature
The objective of this study is to analyze the data available in the literature on therapies and molecules currently in use to improve the prognosis of recurrent cervical cancer.AREAS COVERED: An extensive literature search was conducted by authors to identify relevant trials on various databases. Articles in English published until September 2023 that investigate different pharmacotherapy strategies for the treatment of recurrent cervical cancer, were included. Results of various pharmacological regimens including different combinations of chemotherapy, immune checkpoint inhibitors, DNA damage repair inhibitors and antibod...
Source: Expert Opinion on Pharmacotherapy - December 30, 2023 Category: Drugs & Pharmacology Authors: Ottavia D'Oria Giorgio Bogani Ilaria Cuccu Tullio Golia D'Auge Violante Di Donato Donatella Caserta Andrea Giannini Source Type: research
Advances in non-biological drugs for the treatment of rheumatoid arthritis
Expert Opin Pharmacother. 2023 Dec 21:1-9. doi: 10.1080/14656566.2023.2297798. Online ahead of print.ABSTRACTINTRODUCTION: Rheumatoid arthritis (RA) is a complex autoimmune disease that affects millions of people worldwide, with a systemic impact. This review explores the role of non-biological conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in its management.AREAS COVERED: We discuss the effectiveness and safety of key csDMARDs such as Nonsteroidal anti-inflammatory drugs, corticosteroids, Hydroxychloroquine, Sulfasalazine, Methotrexate, and Leflunomide in relieving symptoms and slowing the progres...
Source: Expert Opinion on Pharmacotherapy - December 21, 2023 Category: Drugs & Pharmacology Authors: Aliki I Venetsanopoulou Paraskevi V Voulgari Alexandros A Drosos Source Type: research
Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?
Expert Opin Pharmacother. 2023 Dec 20. doi: 10.1080/14656566.2023.2298345. Online ahead of print.NO ABSTRACTPMID:38116733 | DOI:10.1080/14656566.2023.2298345 (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - December 20, 2023 Category: Drugs & Pharmacology Authors: Mohammed Alsalmi Jawad Al-Kassmy Woojin Kang Michael Palayew Philippe Huot Source Type: research
Selection of maintenance therapy during first-line treatment of advanced ovarian cancer based on pharmacologic characteristics
Expert Opin Pharmacother. 2023 Dec 18. doi: 10.1080/14656566.2023.2295393. Online ahead of print.ABSTRACTINTRODUCTION: Maintenance therapy with bevacizumab and the poly (ADP-ribose) polymerases (PARP) inhibitors olaparib and niraparib after first-line treatment of advanced ovarian cancer has been approved. However, it is not clear which one should be used for which patients.AREAS COVERED: This paper presents a detailed analysis of data from phase 3 trials in ovarian cancer evaluating bevacizumab (ICON7, GOG-0218), olaparib (SOLO1, PAOLA-1), and niraparib (PRIMA, PRIME). We will discuss how the results of these tirals relat...
Source: Expert Opinion on Pharmacotherapy - December 19, 2023 Category: Drugs & Pharmacology Authors: Hidekatsu Nakai Noriomi Matsumura Source Type: research
